patient view

This page is a research summary built from public sources (FDA, NIH, clinical trial registries). It is not medical advice.Always talk to your doctor about treatment decisions. Drug information here may be incomplete or out of date — verify with your prescriber and the manufacturer's package insert.

drug

save

adalimumab

Marketedupdated 2mo ago

by $ABBV AbbVie Inc.

Approved

annual revenue · 2024–2024peak $9.0B

community read0 votes

Antibody drug with a maximum clinical stage of Approval (across all indications), with 14 approved and 20 investigational indications.

indications

investigational

IBD (Crohn's + UC)Rheumatoid Arthritis

all catalysts(61)

approval · 61

view all 61 catalysts →

News(1)

Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs
“We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.
stat · 2mo ago

brand

Humira

generic

adalimumab

MOA

12.1 Mechanism of Action Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased concentrations of TNF are also found in psoriasis plaques. In Ps, treatment with HUMIRA may reduce the epidermal thickness and infiltration of inflammatory cells. The relationship between these pharmacodynamic activities and the mechanism(s) by which HUMIRA exerts its clinical effects is unknown. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the concentrations of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC 50 of 1-2 X 10 -10 M).

adalimumab

indications

all catalysts(61)

News(1)

Report a data issue

comments(0)

🐶 often sniffed alongside

Trials studying adalimumab